First-in-Class Drug for ADHD Wins FDA Approval

The FDA has granted approval for centanafadine, marketed as Simtriyo, to treat attention deficit-hyperactivity disorder. This drug is indicated for patients aged 6 years and older who weigh at least 20 kg. It functions as a triple reuptake inhibitor, targeting norepinephrine, dopamine, and serotonin to assist with behavioral regulation.

Clinical evidence for this approval stems from four randomized, double-blind, placebo-controlled phase III trials. These studies included adult, adolescent, and pediatric populations. Participants showed significant improvements in ADHD symptom ratings starting as early as week one of treatment.

Common side effects vary by age group. Children often reported rash and decreased appetite. Teens experienced nausea and headaches in addition to appetite changes, while adults reported symptoms such as dry mouth, insomnia, and diarrhea. Healthcare providers should note that the drug label carries boxed warnings regarding the risk of suicidal ideation and the potential for addiction or misuse.

Other precautions for the medication include risks related to increased heart rate and blood pressure, potential psychiatric reactions, and long-term growth suppression in children. The medication is not recommended for children under 6 due to weight loss concerns and is contraindicated for patients using or recently stopping monoamine oxidase inhibitors.

Otsuka expects the medication to become available later this year following the completion of drug scheduling requirements. This approval provides a new pharmacological mechanism for clinicians managing the complex symptoms of ADHD in children and adults.